Transaction #30160 · Form 4 · 0001878313-26-000100
MAIA Biotechnology, Inc. · Stock award · Stock Options
MAIA Biotechnology, Inc. · Transacted September 30, 2026 · Filed October 2, 2026
What does this filing report?
An SEC Form 4 filing for MAIA Biotechnology, Inc. records a stock award involving Stock Options on September 30, 2026. The reported quantity was 32,012. The filing date is October 2, 2026. This is one transaction record; amounts are not allocated among any joint reporting owners.
The acquisition category describes how securities were received. It does not by itself establish a cash purchase of common stock. Read the transaction code definitionsand the original filing before interpreting the amounts.
Transaction details
- Company
- MAIA Biotechnology, Inc.
- Company CIK
- 0001878313
- Security type
- Derivative
- Acquisition type
- Stock award · Code A
- Quantity acquired
- 32,012
- Reported price
- 0
- Reference value
- 0
- Currency
- Currency not specified
- Ownership
- Direct
- Holdings after transaction
- 32,012
- Ownership description
- Not reported
- SEC acceptance time
- Oct 2, 2026, 4:20 PM EDT
- 10b5-1 indication
- Not indicated
Reference value is reported quantity × reported price. It is not a confirmed cash payment or an estimate of a derivative's economic value. A missing currency is not assumed to be USD.
Reporting owners
- Theagene Jean-Manasse ↗
Director
CIK 0001969857
These are the reporting owners named in the filing. Quantities and amounts are not allocated among co-reporters. Roles reflect this filing, not a current profile.
Company listings
This transaction is not mapped to a specific company listing.
Derivative terms
- Underlying security
- Common Stock
- Underlying quantity
- 32,012
- Conversion / exercise price
- 1.18
- Exercise date
- September 30, 2026
- Expiration date
- September 30, 2036
Filing footnotes & remarks
- F1
- The stock options, granted on September 30, 2026 pursuant to the MAIA Biotechnology, Inc's 2021 Equity Incentive Plan, representing the right to buy shares of common stock, vest 100% on the date of the grant and are exercisable beginning as of that date.
Footnotes are reproduced as plain text from the current source filing. For the full context, read the original SEC filing.
This record was updated Eastern Time. This is the stored record update time, not the transaction date. Report a correction.